Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation-Reference-Cited by-同舟云学术

Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation

Published:2021-03 Issue:1 Volume:99 Page:240-272
ISSN:0887-378X
Container-title:The Milbank Quarterly
language:en
Short-container-title:The Milbank Quarterly

Author:

RAIMOND VÉRONIQUE C.¹²^ORCID,FELDMAN WILLIAM B.¹²³^ORCID,ROME BENJAMIN N.¹²^ORCID,KESSELHEIM AARON S.¹²^ORCID

Affiliation:

1. Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital

2. Harvard Medical School

3. Division of Pulmonary and Critical Care Medicine Brigham and Women's Hospital

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1468-0009.12507

Reference58 articles.

1. Medication costs, adherence, and health outcomes among Medicare beneficiaries;Mojtabai R;Health Aff (Millwood),2003

2. Health care spending in the United States and Other high‐income countries;Papanicolas I;JAMA,2018

3. US House of Representatives Ways and Means Committee Staff.A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices. September 2019.https://waysandmeans.house.gov/sites/democrats.waysandmeans.house.gov/files/documents/U.S.%20vs.%20International%20Prescription%20Drug%20Prices_0.pdf. Accessed February 13 2020.

4. ClaxtonG SawyerB CoxC.How does cost affect access to care? Peterson‐Kaiser Health System Tracker. Published January 20 2019.https://www.healthsystemtracker.org/chart-collection/cost-affect-access-care. Accessed February 13 2020.

5. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018;Hernandez I;JAMA,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014;Value in Health;2024-07

2. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure;Value in Health Regional Issues;2024-03

3. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?;The Journal of Clinical Endocrinology & Metabolism;2023-10-17

4. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare;JAMA;2023-04-18

5. The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics;Value in Health;2023-03